Nanoparticles engineered with rituximab and loaded with Nutlin-3 show promising therapeutic activity in B-leukemic xenografts

Clinical Cancer Research (2013) - Comments
pubmed: 23719263 doi: 10.1158/1078-0432.ccr-13-0015 issn: 1078-0432 issn: 1557-3265

Rebecca Voltan, Paola Secchiero, Barbara Ruozi, Flavio Forni, Chiara Agostinis, Lorenzo Caruso, Maria Angela Vandelli, Giorgio Zauli